Sanofi granted U.K. marketing authorization for TIV High Dose

U.K. marketing authorization has been granted for Sanofi Pasteur’s Trivalent Influenza Vaccine High Dose, which is indicated for active immunisation of people 65 years of age and older against influenza disease. The decision means the U.K. is the only European country where TIV High Dose is approved, Sanofi said in a statement. TIV High Dose is included in the Joint Committee on Vaccination and Immunisation advice on influenza vaccines for the 2019/20 influenza season. TIV High Dose is already approved for people 65 years of age and older in the United States, Canada, Australia and Brazil.

https://thefly.com/landingPageNews.php?id=2851247